Jiangsu Recbio Technology Co Ltd
02179
Company Profile
Business description
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Contact
No. 888 Yaocheng Avenue
Medical High-tech District
Jiangsu Province
Taizhou
CHNT: +86 52388820888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
507
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,148.50 | 45.40 | 0.50% |
| CAC 40 | 7,880.87 | 10.19 | 0.13% |
| DAX 40 | 23,745.06 | 5.59 | 0.02% |
| Dow JONES (US) | 46,187.70 | 59.59 | -0.13% |
| FTSE 100 | 9,299.84 | 15.01 | 0.16% |
| HKSE | 26,622.88 | 494.68 | 1.89% |
| NASDAQ | 22,572.06 | 87.99 | 0.39% |
| Nikkei 225 | 45,043.75 | 311.24 | -0.69% |
| NZX 50 Index | 13,132.56 | 20.83 | 0.16% |
| S&P 500 | 6,650.88 | 7.18 | 0.11% |
| S&P/ASX 200 | 8,862.80 | 52.10 | 0.59% |
| SSE Composite Index | 3,862.53 | 34.43 | 0.90% |